RNTXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Rein Therapeutics, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 14, 2026
$0.55−0.04 (-6.49%)
Close on Oct 19, 2026
- Market cap
- $37.03M
- P/E (TTM)
- –
- Dividend yield
- 0.00%
Rein Therapeutics statistics
Financials through Jun 30, 2026, price as of Oct 19, 2026, median of Pharmaceutical Preparations companies for comparison
Valuation
| Measure | Rein Therapeutics | Industry median |
|---|---|---|
| Market Cap | $47.62M | $166.30M |
| Enterprise Value | $3.99M | $88.19M |
| PB Ratio | 0.86 | 2.03 |
| P/TBV Ratio | 1.35 | 2.29 |
Income (trailing twelve months)
| Measure | Rein Therapeutics | Industry median |
|---|---|---|
| Revenue | $0 | $58.34M |
| Operating Income | -$49.46M | -$21.40M |
| Net Income | -$49.76M | -$22.46M |
| EBITDA | -$49.46M | -$16.91M |
| EPS (Diluted) | -$1.59 | -$0.83 |
Returns
| Measure | Rein Therapeutics | Industry median |
|---|---|---|
| Return on Equity (ROE) | -96.4% | -53.2% |
| Return on Assets (ROA) | -80.6% | -40.9% |
| Return on Invested Capital (ROIC) | -145.1% | -32.4% |
| Return on Capital Employed (ROCE) | -87.9% | -38.1% |
Balance sheet
| Measure | Rein Therapeutics | Industry median |
|---|---|---|
| Cash & Short-Term Investments | $43.63M | $61.43M |
| Net Cash (Debt) | $43.63M | $15.35M |
| Net Cash Per Share | $0.51 | $0.66 |
| Equity (Book Value) | $55.20M | $49.09M |
| Book Value Per Share | $0.64 | $1.37 |
| Tangible Book Value | $35.37M | $23.52M |
| Working Capital | $31.74M | $76.81M |
Financial position
| Measure | Rein Therapeutics | Industry median |
|---|---|---|
| Current Ratio | 4.27 | 3.34 |
| Quick Ratio | 4.49 | 2.44 |
Cash flow (trailing twelve months)
| Measure | Rein Therapeutics | Industry median |
|---|---|---|
| Operating Cash Flow | -$18.83M | -$12.35M |
Efficiency
| Measure | Rein Therapeutics | Industry median |
|---|---|---|
| Asset Turnover | 0.00 | 0.39 |
| Revenue Per Employee | $0 | $404.87K |
| Profits Per Employee | -$4.98M | -$703.34K |
| Employee Count | 10 | 74 |
Dividends and yields
| Measure | Rein Therapeutics | Industry median |
|---|---|---|
| Earnings Yield | -104.5% | -23.3% |
| Dividend Yield | 0.00% | 1.82% |
| Buyback Yield | -115.5% | -0.59% |
| Shareholder Yield | -115.5% | 0.00% |
| Dividend Per Share | $0.00 | $0.83 |
| Years of Dividend Growth | 0 | 0 |
Shares
| Measure | Rein Therapeutics | Industry median |
|---|---|---|
| Shares Outstanding | 86,267,000 | 58,127,000 |
| Shares Change (YoY) | 71.1% | 10.9% |
| Shares Change (QoQ) | 205.9% | 0.54% |
| Float | 77,969,100 | 49,136,700 |
| Shares Held by Insiders | 9.62% | 11.6% |
| Shares Held by Institutions | 47.3% | 59.4% |
Scores
| Measure | Rein Therapeutics | Industry median |
|---|---|---|
| Altman Z-Score | -8.02 | -0.22 |
| Piotroski F-Score | 2 | 4 |
Calculated by StockData from Rein Therapeutics's SEC filings and the latest closing price. Hover a measure to see its formula. The grey column is the median of companies in the same industry group (two-digit SIC code); green or red marks a better or worse value than that median.